Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000020416
- Lead Sponsor
- Japanese Society for Cancer of the Colon and Rectum
- Brief Summary
Whether unadjusted analysis or adjusted analysis was established, regorafenib and trifluridine/tipiracil showed a similar efficacy in the overall survival of? patients with metastatic colorectal cancer refractory to standard treatments in the real-world setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
1) Prior therapy with regorafenib or TAS-102 2) Active infections 3) Symptomatic brain metastasis 4) Active double cancers 5) Serious complications 6) Uncontrolled thromboembolism 7) Comorbidity with systemic steroid therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression-free survival, response rate, disease control rate, time to treatment failure, time to ECOG PS >=2, incidence of adverse events, detail of subsequent treatment, and comparison between patients with initial dose reduction and patients without it.